In this MasterClass, Dr. Starr discusses the algorithm for identifying dry eye flares in a preoperative setting. By the end of this class, you will learn how to manage these complex patients.
This activity is supported by an unrestricted educational grant from Kala Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Christopher E. Starr, MD
Associate Professor of Ophthalmology
Director, Refractive Surgery Service
Director, Ophthalmic Education
Weill Cornell Medicine
New York Presbyterian Hospital
New York, NY
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Christopher E. Starr, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Aldyra, Allergan, Blephex, Bruder, Dompé, Eyevance, Kala Pharmaceuticals, Johnson & Johnson Vision, Novartis, Oyster Point, Quidel, Sun Pharma, Tarsus, Tearlab, and Visionology. Stock/Shareholder: Essiri Labs, Visionology.
Evolve and The Fundingsland Group staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, or Kala Pharmaceuticals.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Eric D. Donnenfeld, MD
Marjan Farid, MD
Jason J. Jones, MD
Eva I. Liang, MD, FACS
Carlton Yuen, MD
